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A potassium loading study was performed in acutely nephrectomized 
rats to determine the extrarenal effects of diuretics on potassium 
tolerance. Four diuretics were used - furosemide, hydrochlorothiazide, 
spironolactone, and bumetanide. In all animals studied, there was no 
significant difference between animals given diuretics and control 
animals in the observed increment in plasma potassium concentration. 
Keeping in mind the difficulties inherent in interpreting whole 
animal studies, these results suggest that: 
1) If the recently postulated furosemide-inhibited cation 
cotransport mechanism does exist in the rat, then at the least this 
transport mechanism is not the dominant mechanism for determining 
potassium balance in the whole animal model. 
2) There is no thiazide-induced extrarenal impairment or 
improvement of potassium tolerance. 
3) Blockade of aldosterone with spironolactone does not cause 




Diuretics are among the most commonly used pharmacologic agents 
in clinical medicine. They are classified according to chemical 
structure and by their major sites of action in the kidney. Yet, 
with the exception of the carbonic anhydrase inhibitors, relatively 
little is known about their mechanisms of action. That this should 
be so goes hand in hand with the fact that the intimate details of 
the structure and biochemical functions of the renal epithelium 
remain obscure. Elucidation of the mechanisms of action of the 
various classes of diuretics would doubtless provide invaluable 
insight into the mechanisms of ion transport in the tubular cell of 
the kidney, and in a broader sense to our understanding of renal 
physiology as wel1. 
It appears that the actions of many diuretics are not limited 
to the renal epithelium. For example, furosemide has been shown to 
cause a prompt increase in venous capacitance which precedes its 
diuretic effect (1). This has been useful in the treatment of 
pulmonary congestion and pulmonary edema in the setting of elevated 
left ventricular filling pressure associated with acute myocardial 
infarction (1). Furosemide has also been used as an antihypertensive, 
as have diuretics of other chemical groups including thiazides and 
aldosterone inhibitors. Their effect of lowering blood pressure has 
been demonstrated to persist even after their diuretic effect has 
ceased (2-4). 
Much of the work in this laboratory has been devoted to the study 
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of the regulation of potassium balance by the kidney and by extrarenal 
mechanisms. In view of the ubiquitous use of diuretics in clinical 
medicine, and in view of data suggesting that they have extrarenal 
effects not only on hemodynamic regulation as mentioned above but on 
regulation of ion transport as well, it seemed of interest to pursue 
study of the effects of these drugs on extrarenal potassium disposal. 
The background for this work is discussed in detail in later sections 
and briefly below. 
1. Furosemide in large doses is often used to treat patients with 
acute renal failure in an effort to convert an oliguric state to a 
non-oliguric one. When successful, this effect is thought to involve 
changes in renal vasuclar resistance and renal blood flow (5-9). More 
recently, furosemide has been used in defining an ion cotransport 
mechanism which exists in several cell systems, including avian (10-13) 
and human red blood cells (14-18) and the loop of Henle (19 20). This 
system, which transports Na, K, and Cl intracel1ularly, is inhibited 
by furosemide. The ability of furosemide and other aminobenzoic acid 
derivatives such as bumetanide to act as inhibitors of the transport 
system is directly correlated with their diuretic potency (10), leading 
to speculation as to the significance of this mechanism within the 
renal epithelium. Moreover, if this cotransport system has major 
significance in the whole animal, then its effects on ionic, specifically 
potassium, balance must be considered. In the setting of acute renal 
failure, if use of furosemide could result in decreased potassium 
tolerance due to inhibition of cotransport, then there is a potential 
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for development of life-threatening hyperkalemia. 
2. Thiazides are known to lower plasma potassium in certain 
disease states where hyperkalemia is found in the presence of normal 
renal function (21-24). Recently there has been a case report 
involving hyperkalemia associated with hypertension in which both 
abnormalities were corrected with thiazide administration (24). 
Interestingly, however, urinary K excretion did not significantly 
increase with the diuretic, implying that correction of the 
hyperkalemia was not due to increased potassium losses. In short, 
an extrarenal effect of thiazides on potassium disposal is suggested. 
3. Aldosterone has recently been shown to have an extrarenal 
effect on potassium disposal (25). The effect of mineralocorticoids 
on extrarenal potassium homeostasis is discussed in detail in the 
following section. Briefly, mineralocorticoids appear to enhance 
K uptake by extrarenal tissues (26-28), and extrarenal K tolerance 
is diminished in their absence (29,30). By extrapolation, one would 
expect then that mineralocorticoid inhibition, for example with such 
agents as the aldosterone antagonist spironolactone, might have an 
opposite effect on extrarenal K balance.. 
There has been little work done on the role of diuretics on ion 
transport outside the kidney. We therefore undertook this study to 
examine the effects of diuretics of three chemical families on 
extrarenal potassium disposal. The diuretics used were furosemide. 
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bumetanide, hydrochlorothiazide, and spironolactone 
an understanding of extrarenal potassium regulation 
this project, a brief overview of factors currently 
involved in this regulation follows. 
(Figure 1). As 
is essential to 




A wealth of literature has been devoted to the discussion of the 
regulation of extracellular potassium concentration. Extracellular 
potassium represents only 2°l of total body potassium, or approximately 
65 mEq in a 70 kg man. Elucidation of the complex mechanisms by which 
this relatively small pool of potassium is controlled has proved to 
be a fascinating albeit extremely difficult task. While our understanding 
of the cellular mechanisms of potassium homeostasis has greatly 
expanded in recent years, it is still limited, and much of the regulation 
of cellular potassium transport as well as the broader area of cellular 
ion transport remains to be fully evaluated. 
The kidney is a major regulator of potassium homeostasis; renal 
mechanisms are important determinants of extracel1ular potassium 
balance in chronic disease or health. However, it has become increasingly 
clear that extrarenal mechanisms play an important role in overall 
potassium homeostasis, particularly in settings of acute potassium 
imbalance (25). With the use of newer techniques and with increasing 
utilization of cellular probes in the form of drugs and hormones, our 
understanding of extrarenal potassium regulation has broadened. 
Moreover, a greater appreciation of the mechanisms of extrarenal 
cellular potassium transport and regulation can be applied to further 
our understanding of renal mechanisms of K transport, and to our 
understanding of the physiology of the kidney. 
There are a number of extrarenal factors which interact to a 
greater or lesser degree with chronic as well as acute K homeostasis. 
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The details of these interactions have obviously not been fully worked 
out; however, it has become clear that renal potassium excretion may 
well not be the most important factor in the handling of an acute 
K load (25). It has been shown in humans (31-33), in dogs (31), and 
in rats (34) that less than 50% of an acute exogenous K load is 
excreted by the kidney in the first four to six hours following 
administration (25). The greater part of the remainder of the K load 
is transported into the intracellular compartment by extrarenal mechanisms, 
thus defending the extracellular fluid from life-threatening hyperkalemia. 
These mechanisms have been reviewed extensively in a recent review by 
Bia and DeFronzo (25), and will be discussed only briefly here. 
Acid-Base 
It has long been appreciated that acid-base balance can affect the 
distribution of potassium. Fenn and Cobb in 1934 showed that lowering 
the pH of a skeletal muscle preparation caused movement of K out of 
muscle cells into the surrounding medium (35) and suggested that there 
was a connection between intra- and extracellular hydrogen ion and 
potassium ion concentrations. Since then it has been the general 
conclusion that intra- and extracel1ular acid-base balance and potassium 
status are integrally and reciprocally related (36). Acidosis causes 
the plasma K concentration to increase due to displacement of K 
extracel1ularly in exchange for the buffering of excess H ions 
intracellularly, with the opposite exchange occuring during alkalosis. 
Burnell et al. quantitated the increments in K and pH in five patients 
with various types of acid-base disturbances and calculated that, on 
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the average, for every 0.1 unit change in extracellular pH there was 
an inverse change of 0.6 mEq/L in the serum K concentration (37). 
This numerical relationship is commonly used as a guideline to estimate 
a corrected K concentration in the presence of an acid-base disturbance. 
However, it has been pointed out in recent years that the relationship 
between hydrogen ion and potassium concentrations is far more complex 
than has been assumed (25,36), and that the variation of plasma K 
increments observed with an 0.1 unit pH change is considerable (25). 
As noted by Bia and DeFronzo (25) and by Adler and Fraley (38), a 
number of factors, including the nature of the disturbance (i.e. 
metabolic vs. respiratory), the type of anion accompanying an increase 
in hydrogen ion concentration, the duration of acidosis, and the extent 
of intracellular buffering, as well as the type of imbalance itself 
(i.e. acidosis vs. alkalosis) affect the relationship between the 
two ions. Moreover there is evidence that the plasma bicarbonate 
concentration also may alter potassium distribution, independent of 
the blood pH (38,39). Although the original observation of the 
reciprocal relationship between hydrogen ion and potassium concentration 
has been confirmed repeatedly, the complexity of the relationship has 
been underestimated, and the exact nature of the interactions between 
acid-base balance and potassium regulation remains to be defined. 
Hormones 
I. Insulin 
Much effort has been concentrated recently on determining the 
effects of various hormones on extrarenal K regulation. Of the major 
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hormones known to affect potassium homeostasis, insulin is probably 
the best described. Harrop and Benedict (40) and Briggs et al. (41) 
in 1923 noted that insulin administered to the intact animal produced 
a decrease in serum potassium concentration. This observation has 
subsequently been demonstrated and further described by a number of 
investigators (32, 42-47) and it is now well established that insulin 
plays an important role in the disposal of an acute potassium load. 
It has been shown by several groups that infusion of KC1 resulting in 
an elevation of plasma K to a significant degree of hyperkalemia 
(i.e. an increase of greater than 1.0-1.5 mEq/L (25)) causes an 
increase in peripheral insulin levels and a stimulation of pancreatic 
insulin secretion (45,46). The relative clinical importance of this 
relationship may be evident in the setting of acute hyperkalemia due 
to hemolysis, rhabdomyolysis, severe crush injuries, and burns, etc. 
Perhaps more importantly, however, it has recently been demonstrated 
that basal insulin levels play a role in potassium homeostasis (43). 
DeFronzo et al. (43) have shown that in dogs given a relatively small 
KC1 infusion (0.375 mEq/kg/hr), serum K increased by only 0.5-0.7 mEq/L, 
remaining within the normal physiologic range, and under these conditions 
basal insulin levels remained unchanged. However, when somatostatin, 
a potent inhibitor of insulin and glucagon secretion, was infused with 
KC1, serum K levels doubled over control values. Moreover, suppression 
of basal insulin secretion in normal dogs, normal human subjects, and 
maturity-onset diabetics by somatostatin in the absence of KC1 infusion 
was associated with a significant rise of baseline plasma K concentrations. 
This effect was independent of and preceded any changes in plasma glucose 
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and was also noted to be present in the absence of any change in renal 
K excretion, implying that the effect of basal insulin secretion on 
plasma K concentration was extra-renal in nature. That this was an 
effect of lack of insulin rather than glucagon was supported by the fact 
that in juvenile-onset diabetics lacking endogenous insulin secretion, 
no change in plasma K concentration was seen after infusion of 
somatostatin. A permissive role for basal insulin levels on K regulation 
is thus suggested. It should be noted, however, that peripheral 
measurements of insulin levels may not accurately reflect the secretion 
of insulin by the pancreas. Blackard and Nelson (48) have demonstrated 
that portal and peripheral vein insulin concentrations differ by a 
ratio of approximately 2-3:1. It has been shown that extremely small 
increments of plasma insulin (e.g. 25^cU/ml) can cause stimulation 
of K uptake by various tissues (49). Hence the postulated permissive 
role of basal insulin secretion on tissue K uptake must be modified 
to include the possibility that portal insulin levels may be 
sufficiently elevated to actively augment hepatic K uptake in the absence 
of any measurable increase in peripheral insulin levels (25). In this 
instance, use of a C-peptide assay as an analytic tool for measuring 
pancreatic insulin secretion might be a reasonable alternative. 
In the absence of insulin the ability to tolerate an acute potassium 
load is markedly impaired. This has been demonstrated in pancreatectomized 
dogs (44,45,50) as well as in dogs, rats, and humans infused with 
somatostatin (34,43,46,47,51,52) and is independent of any change in 
renal K excretion. The ability to dispose of a potassium load 
intracel1ularly is restored when insulin is replaced. The clinical 
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importance of this mechanism is evident in such obvious ways as the 
use of insulin (along with glucose) in the treatment of life-threatening 
hyperkalemia. It is tempting to speculate that in the clinical setting 
of insulin lack, that is in the setting of diabetes, the not infrequent 
occurrence of hyperkalemia may be due at least in part to the 
insulinopenia itself as well as to the increase observed in plasma 
tonicity and, as recently postulated, in some cases also to concomitant 
hypoaldosteronism (26). 
It has been shown by several groups that insulin-enhanced cellular 
K uptake involves muscle (53-57) and liver (58-60), which serve as the 
major body potassium storage pools. That the stimulation of cellular 
K uptake is distinct from the action of insulin on cellular glucose 
uptake is supported by the observations that a) the temporal courses 
of potassium and glucose movement differ (61), b) the potassium uptake 
can be shown to occur unchanged in glucose-free medium (55,56), and 
c) potassium uptake can be stimulated maximally by insulin concentrations 
too small to effect glucose transport (62). 
The cellular mechanism by which K uptake is stimulated by insulin is 
thought to involve hyperpolarization of the cell membrane. Zierler et 
al. (55-57) in a system using rat skeletal muscle have shown that the 
movement of potassium is not sufficiently large enough nor does it occur 
rapidly enough to explain the insulin-induced increase in the transmembrane 
potential difference, and have surmised that the movement of potassium 
occurs as the result of the hyperpolarization rather than as its cause. 
They have suggested that perhaps K movement is enhanced due to some 
alteration of the permeability of the cell membrane secondary to the 
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hyperpolarization which allows the ion (and perhaps other substrates 
such as glucose) to move passively intracellularly (55,57). 
II. Catecholamines 
That catecholamines are involved in the regulation of potassium 
homeostasis was first noted by D'Silva, who in the 1930s demonstrated 
that injection of epinephrine into normal cats caused a transient 
increase in plasma potassium which was followed by a sustained 
decrease in plasma potassium (63,64). This initial hyperkalemic 
effect was presumed to be the result of increased hepatic potassium 
release, as supported by the observation that there was an increase 
in hepatic venous potassium concentration after epinephrine injection. 
The effect of sustained hypokalemia that followed was felt to be 
secondary to increased tissue uptake of potassium. Since then, 
catecholamines have been shown to play a significant role in the 
regulation of potassium in both the kidney and in extrarenal tissues 
(25,34,65-68). 
DeFronzo et al. (68) recently demonstrated that infusion of KC1 
with epinephrine into normal humans leads to a marked inhibition of 
the increased renal K excretion that is observed with KC1 infusion 
alone. Yet the rise in plasma K was less in subjects who had received 
both KC1 and epinephrine as compared to subjects who received KC1 
alone, indicating that potassium tolerance is improved in the presence of 
catecholamines, presumably due to enhanced cellular uptake. Increased 
cellular uptake of K in response to catecholamine has been demonstrated 
clearly in skeletal muscle, the major potassium storage tissue (69-72), 
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and some investigators have also reported an increased uptake in liver 
(69-71). That this effect is distinct from the action of insulin has 
been demonstrated by Petit and Vick (73) in studies of pancreatectomized 
dogs. Response to epinephrine in experimental animals did not differ 
significantly from pancreatectomi zed controls, indicating that the 
enhanced cellular uptake of K did not depend on the release of insulin (73). 
Moreover, hyperglycemia per se was also found not to affect the response 
to epinephrine (74). 
The mechanisms by which catecholamines bring about their biphasic 
effects on plasma K concentration have been worked out to some extent. 
Lockwood and Lum (69,75) and Todd and Vick (76) used adrenergic agonists 
and antagonists to show that the early hyperkalemic effect of 
catecholamines depends on both ©<- and ^-adrenergic properties, while 
the secondary hypokalemic effect resulting from enhanced cellular 
uptake is apparently a purely ^-adrenergic function. These authors 
have shown that p,-agonist activity is protective against a KCl-induced 
hyperkalemia, and that this protective effect can be abolished by the 
^-blocking agent propranolol. Further work with more selective ^ and 
agents have shown that the stimulation of cellular K uptake is most 
likely due to specific ^,-agonist activity (e.g. by the selective ^>- 
agonists salbutamol and soterenol) and can be prevented by selective 
^-antagonists (e.g. Butoxamine). Of clinical interest in this regard 
is the report by Wang and Clausen of the successful treatment of attacks 
in hyperkalemic familial periodic paralysis by salbutamol inhalation, 
presumably due to stimulation of cellular potassium uptake (77). 
Recently, reports of impaired K tolerance following ^-blockade in 
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man have prompted the study of the effects of ^-blockade itself on 
potassium balance (67,68). As described above, infusion of KC1 with 
epinephrine into normal subjects causes an inhibition of the increased 
renal K excretion observed with KC1 infusion alone (68), yet plasma K 
rises less in those subjects given KC1 and epinephrine than in those 
given KC 1 alone, ^-blockade in the form of propranolol abolishes 
this effect of epinephrine. Interestingly, however, when propranolol 
is given with KC1 infusion and no epinephrine is given, a greater 
increase in plasma K is noted than when KC1 is given alone, suggesting 
that basal epinephrine levels may play a role in K regulation, as is 
thought to be the case with basal insulin levels (67,68). 
Although the pharmacology of the catecholamine effect on cellular 
K uptake has become more clear in recent years, the mechanisms by which 
the epinephrine-stimulated K transport occurs have yet to be worked out. 
Moreover, the effect of potassium itself on regulation of catecholamine 
production is not known. It has been suggested that potassium may act 
as a stimulus to catecholamine release by the adrenals (78,79). Vogt 
demonstrated that injection of KC1 into the celiac artery causes increased 
release of sympathomimetic amines into the adrenal vein (79), and 
Silberstein et al. have demonstrated that incubation of adrenal glands 
in media with elevated potassium concentrations results in increased 
activity of tyrosine hydroxylase (the first enzyme in the biosynthetic 
pathway of catecholamines) and in an increase in the amount of epinephrine 
released from the gland (78). However, Vogt failed to report the dose of 
KC1 infusion used in her system, and the 50 mM K concentration of the 
medium used by Silberstein et al. seems hardly physiologic. The complex 
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interrelationships between potassium regulation and catecholamine 
synthesis, function, and effect are obviously still far from being 
fully understood. 
III. Mineralocorticoids 
The effect of mineralocorticoids in augmenting potassium secretion 
by the kidney has been described (80-83). This kaliuretic effect 
is observed in response to acute mineralocorticoid exposure as well 
as with prolonged treatment in contrast to the sodium "escape" phenomenon 
that occurs in the kidney with prolonged mineralocorticoid exposure (80). 
The action of these agents in the kidney has been localized to sites in 
the distal tubule and collecting system (84). 
Hyperkalemia is known to act as a stimulus to aldosterone secretion 
(85,86). It has been suggested that in the absence of an intact renin- 
angiotensin system changes in potassium concentration may be the major 
regulator of aldosterone production (87). Laragh and Stoerk demonstrated 
that increased K intake resulted in aldosterone hypersecretion (88). 
Subsequently, Blair-West et al. demonstrated that KC1 infusion leading 
to increased plasma K concentration within the normal physiologic range 
had an aldosterone-stimulating effect resulting in a significant elevation 
in adrenal vein aldosterone levels, and postulated that the effect 
observed earlier by Laragh and Stoerk had been due to a direct action of 
the increase in plasma K on the adrenal gland (89). Since then the 
biochemical synthetic pathway for aldosterone in the zona glomerulosa 
of the adrenal has been worked out, and the fact that potassium stimulates 
both an early and a late step in aldosterone synthesis (notably the 
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conversions of cholesterol to deoxycorticosterone and corticosterone 
to aldosterone (90)) is consistent with their earlier observations (26). 
That an increase in plasma K causes increased aldosterone secretion 
makes teleologic sense since a major physiologic effect of aldosterone 
is to increase K excretion via the kidney. However, aldosterone is 
thought to have significant effects on potassium regulation by 
extrarenal tissues as well. 
Aldosterone is known to cause a decrease in the Na/K ratio in 
secretions of salivary glands, sweat glands, and colon (91-94). 
However, there have been conflicting views as to the effect of 
mineralocorticoids on K transport in other extrarenal tissues known to 
contain large amounts of exchangeable intracellular potassium, notably 
muscle and liver. Several groups have reported a decrease in potassium 
content of muscle after exposure to aldosterone (95,96); in contrast 
other groups have shown no change in muscle potassium content (27,28). 
Moreover it has been suggested that increased uptake of K occurs but 
that perhaps the potassium increment in any one tissue is too small to 
be measured (28,97,98). Bia and DeFronzo (25) have pointed out that 
these differences may have risen from a number of discrepancies among 
studies: species differences, failure to examine overall K balance, 
acid-base status, systemic hemodynamics, differences in aldosterone 
and potassium doses, and differences in the levels of other potassium- 
regulatory hormones. These authors, however, feel that mineralocorticoids 
do cause an enhancement of K uptake by extrarenal tissues (25). In vivo 
studies in normal rabbits infused with aldosterone (27) and in 
adrenalectomized rats treated with deoxycorticosterone acetate (28) have 
I 
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shown that mineralocortioid administration decreases plasma K and that 
this decrease cannot be explained by increased renal or fecal K losses. 
In a similar vein, in adrenalectomized dogs an increase in plasma K 
was observed which could not be explained by decreased K losses in 
urine or stool (29). Moreover, in nephrectomized rats, hyperkalemia 
resulting from KC1 loading was significantly greater in adrenalectomized 
animals versus controls (30). Furthermore, in the syndrome of 
hyporeninemic hypoaldosteronism in man in which hyperkalemia is often 
the presenting complaint, it has been noted that replacement of 
mineralocorticoid results in correction of the elevated plasma K without 
a concomitant increase in urinary K excretion (26). 
Hence it appears that in the whole animal mineralocorticoid 
enhances extrarenal potassium disposal (25), and likely plays an 
important role in overall extrarenal potassium homeostasis. This is 
probably the result of mineralocorticoid-induced increased cellular 
uptake of K by extrarenal tissues; however, it has been difficult to 
document this in isolated tissue systems, and the mechanisms by which 
this uptake occurs remains obscure. 
IV. Gluoocorticoids 
Glucocorticoids have been shown to produce a transient increase in 
renal potassium excretion which is distinct from the kaliuresis induced 
by mineralocorticoids (25). Some investigators have also reported a 
transient increase in plasma K with acute glucocorticoid administration 
(99,100),, suggesting that there is an extrarenal effect of these 
hormones on K homeostasis. Studies done in hyperkalemic adrenalectomi$d 
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dogs in which chronic cortisone administration corrected the plasma K 
imbalance in the absence of a significant increase in renal K excretion 
support this postulate (101). Also, recent work done in human red 
blood cells has demonstrated that exposure to glucocorticoids causes an 
increase in ouabain sites (102). This respresents an increase in the 
number of Na-K ATPase pump sites, which may be the cellular mechanism 
responsible for the seemingly increased capacity to pump K 
intracel lularly (102). 
The effects of glucocorticoids on extrarenal tissues has been 
relatively unexplored with the exception of the gastrointestinal tract. 
Glucocorticoids are known to affect electrolyte transport across the 
intestinal epithelium, resulting in an increase in the transepithelia 1 
potential difference (103-105). In adrenalectomized rats, secretion of 
K and reabsorption of Na by colonic epithelial cells decreases, and there 
is a reduction in the transepithelial potential difference (105). 
Physiologic doses of dexamethasone replacement restore electrolyte 
transport and the potential difference to normal levels (105). Charney 
et al. (103) demonstrated that there is an association between intestinal 
electrolyte transport and the activity of mucosal Na-K ATPase activity. 
Administration of mineralocorticoid caused an increase in K secretion and 
a decrease in Na reabsorption in the intestinal epithelium, and this was 
felt to be related to the concomitantly increased ATPase activity. 
However, Binder more recently has shown a temporal distinction between 
the increase in membrane potential difference resulting from electrolyte 
transfer and the increase in the Na-K ATPase activity and has suggested 
that the increase in K transport seen with administration of dexamethasone 
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is not the result of increased enzyme activity as Charney et al. had 
postulated. It should be noted, however, that it is clear that the 
rate of K secretion is linked to the activity of the Na-K ATPase in 
the colonic epithelium, as has been recently confirmed by Hayslett et al. 
(106), albeit the glucocorticoid-induced increased K secretion may not 
operate via this mechanism. 
V. Glucagon 
In light of the major effects of insulin on extrarenal K balance, 
it would seem to follow that its endocrine pancreatic counterpart 
glucagon should also play a role in K homeostasis. A transient hyper- 
kalemic effect of glucagon infusion distinct from its glycogenolytic 
action has indeed been identified (107,108). However, these studies 
were performed using pharmacologic doses of glucagon, and the effect 
of smaller, more physiologic amounts of the hormone on K balance 
remains to be established. 
Cotransport 
The cation cotransport system is a relative newcomer to the array 
of possible regulators of potassium homeostasis. A number of transport 
systems are known to operate within cell membranes to regulate intra- 
and extracellular concentrations of ions and organic compounds. In the 
particular case of potassium, two systems of K movement have been 
described: 1) the well-defined, ATPase-driven, ouabain-sensitive Na-K 
pump which causes Na efflux and K influx at the expense of energy in the 
form of ATP, and 2) passive K efflux which allows potassium to "leak" out 
of cells down its concentration gradient. Recently there has been 
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described a third form of ion cotransport which has been recognized in 
a variety of tissues including avian erythrocytes (10-13), mouse fibro¬ 
blasts (114), human erythrocytes (14-18), Ehrlich ascites tumor cells 
(111.115) , as well as the loop of Henle (19,20), While there has been 
a great deal of speculation about the exact nature of the system, it 
now appears that this cotransport mechanism is capable of producing 
net Na and K movement into cells and is dependent on the presence of 
extracellular chloride (15,110,111,113). Geek et al. in a model using 
Ehrlich ascites tumor cells have shown that the net flux of all three 
ions occurs inwardly, with an apparent stoichiometry of 1 K+: 1 Na+: 
2 Cl" (19, 114). 
That this cotransport mechanism is distinct from the better known 
Na-K ATPase pump is made clear by the fact that it is ouabain-insensitive 
(10,11,14-T7,114,115). In the presence of ouabain, the Na efflux and 
K influx of the Na-K ATPase pump ceases, but the cotransport flux 
continues. However, the cotransport mechanism is subject to hormonal 
and pharmacologic manipulations, and may also be sensitive to cellular 
volume (12,113,114,116,117), and is inhibited by propranolol (12) and by 
diuretic agents of the aminobenzoic acid family including furosemide 
(10.14.18.20.114.115) and bumetanide (10). 
Energy for the cotransport process is probably derived from the 
Na (and perhaps also Cl) electrochemical potential difference (14,109). 
By coupling potassium to the process of Na movement, it can be effectively 
transported against its own concentration gradient. This mechanism would 
therefore fall under the category of secondary active transport. As 
recently reviewed by Aronson (119), secondary active transport mechanisms 
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cause the transport of one substnace against its concentration gradient 
by coupling its movement to the movement of another substance down a 
favorable gradient, and does not involve direct linkage to a metabolic 
process. Such mechanisms have been described in a variety of tissues 
in which the transport of amino acids, sugars, and ions are coupled 
to Na movement (109). This is as opposed to primary active transport in 
which transport is directly linked to a metabolic process. The Na-glucose 
cotransport that occurs in the proximal tubule is a well-described 
example of the former; the Na-K ATPase pump ubiquitous in cells is an 
example of the latter. Hence with secondary active transport electro¬ 
chemical ly unfavorable events can by effected by coupling to electro- 
chemically favorable ones without the direct expenditure of metabolic 
energy. In the cotransport mechanism described above, K transport would 
be coupled to the flow of Na down its electrochemical gradient. In this 
case Cl also moves down its concentration gradient, and probably 
contributes to the transport of potassium. 
While the entity of this particular cotransport model seems well 
established, its physiologic function remains to be explained. Several 
authors have proposed that it operates in opposition to the Na-K ATPase 
as a regulator of cellular volume (11,12,113,114). It may also serve as 
a mechanism for transporting K into cells. Of particular interest to 
this study is the fact that drugs with diuretic properties are known to 
inhibit the cotransport system (10,14,18,20,114,115,119). Moreover, 
Palfrey et al. (10) have shown that within this class of agents, diuretic 
potency is directly related to inhibitory ability. That natriuretic 
effect should be directly correlated to the ability to specifically 
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inhibit the cotranport mechanism is a provocative finding, and it is 
tempting to speculate that this is the mechanism for "active" chloride 
reabsorption in the thick ascending loop of Henle as has been 
suggested (19,20). That this would have far-reaching implications in 
the understanding of the physiology of the renal epithelium is evident. 
However, this remains speculation, and the true physiologic importance 




Materials and Methods 
In order to evaluate the extrarenal effects of diuretics on 
potassium tolerance in acutely nephrectomized rats, a potassium 
loading study was performed in male Sprague Dawley rats (Charles River, 
Boston, MA). All rats weighed between 225-265 grams and were divided 
into the following four groups: 
Group la - Furosemide group 
Six rats received an acute intravenous dose of furosemide 
(20 mg/kg) 30 minutes prior to the infusion of KC1 (Figure 2 
In a separate study this dose of furosemide was shown to 
induce a diuresis in rats. 
Ib - Furosemide control group 
Six rats received an intravenous dose of D^W equivalent in 
volume to an appropriate furosemide dose 30 minutes prior 
to the infusion of KC1. 
Group 11a - Hydrochlorothiazide (HCTZ) group 
Six rats receive an acute intravenous dose of HCTZ 
(5 mg/kg) 30 minutes prior to the infusion of KC1 (Figure 2) 
The HCTZ was dissolved in 32% ethanol in D^W. This dose of 
HCTZ was shown to induce a diuresis in rats in a separate 
study. 
IIb'- Hydrochlorothiazide control group 
Six rats received an intravenous dose of 32% ethanol in D^W 
equivalent in volume to an appropriate HCTZ dose 30 minutes 
prior to the infusion of KC1 
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Group Ilia - Spironolactone group 
Six rats received spironolactone (10 mg/kg) subcutaneously 
24-30 hours prior to study. This dose was repeated 210 
minutes prior to KC1 infusion (Figure 2). The spironolactone 
was dissolved in DMSO. 
111b - Spironolactone control group 
Six rats received a dose of DMSO equivalent in volume to 
an appropriate spironolactone dose 24-30 hours prior to 
study, and again 210 minutes prior to KC1 infusion. 
Group IVa - Bumetanide group 
Three rats received bumetanide (0.25 mg/kg) intravenously 
30 minutes prior to KC1 infusion (Figure 2). The bumetanide 
was dissolved in 10% ethanol in D^W. 
IVb - Bumetanide control group 
Three rats received an intravenous dose of 10% ethanol in 
DgW equivalent in volume to an appropriate dose of 
bumetanide 30 minutes prior to KC1 infusion. 
During each K loading study, a diuretic treated rat was studied with a 
concomitant control in order to control for time-related changes in 
each parameter examined. 
All animals were maintained on 15 grams of Standard Purina Rat 
Chow (Na and K content equal to 2.5 and 4.0 mEq/day, respectively) for 
4-7 days before study. All rats consumed the entire 15 grams of chow 
each day. All rats were allowed free access to water. 
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Potassium loading study 
Rats were fasted from the evening prior to study. In the case of 
animals in Group Ilia (spironolactone) and 111b (DMSO), a dose of the 
appropriate drug was administered subcutaneously 24-30 hours prior to 
study and again at approximately 210 minutes before KC1 infusion of the 
day of study. On the day of study, the animals were anesthetized with 
Inactin (Promonta, Hamburg, Germany), 12 mg/ 100 gm body weight 
intraperitoneally. Surgery was begun approximately 15 minutes after 
anesthesia. Body temperature was maintained between 37-38° by means of 
a warming board and an overhead desk lamp; temperature was monitored by 
rectal thermometer. 
A midline skin incision was made in the neck and a tracheostomy 
tube inserted to ensure adequate ventilation. The right external jugular 
vein and the left carotid artery were then cannulated with PE-50 tubing. 
All test substances were infused through the venous catheter and all 
blood samples were withdrawn through the arterial catheter. Blood 
pressure was measured via the carotid catheter. 
Following neck surgery a midline abdominal incision was made and 
bilateral nephrectomy performed. The blood supply to the adrenal glands 
was left intact. All animals received a 1% body weight bolus of 0.15 M 
NaCl over 20 minutes following neck surgery, and a maintenance infusion 
of 0.15 M NaCl at 0.35 ml/ 100 gm body weight/ hour thereafter. A 
Harvard pump (Harvard Apparatus, Mill is, MA) was used to deliver all 
infusions. The abdominal incision was closed with surgical staples. 
Following an equilibration period of approximately 60 minutes 
(T = -60 to T = 0, see Figure 2), two carotid blood samples (E-j and 
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E^) were obtained 15 minutes apart (T = 0 and 15) for analysis of 
equilibration period plasma Na and K concentrations. Immediately 
following the second blood sample, an intravenous dose of the 
appropriate diuretic or its control substance was given in Groups 
la and lb, 11a and 11b, and IVa and IVb, temporarily interrupting the 
maintenance NaCl infusion for approximately one minute. The volume 
of the dose of drugs and controls varied between 0.40 and 0.50 ml. 
No drug was given at this time in Group Ilia and 111b. Two more 
carotid blood samples (B-j and B^) were obtained 15 minutes apart 
(T = 30 and 45) for analysis of baseline plasma Na and K concentrations. 
At T = 45 minutes, the saline infusion was replaced with an infusion 
of 0.5 M KC1 administered at 0.35 ml/ 100 gm body weight/ hr to deliver 
0.17 + 0.02 mEq of potassium per 100 gm body weight per the hour period 
of KC1 infusion. Four carotid blood samples (T-j , Tg, T^, and T^'at1 
T = 75, 90, 105, and 120 minutes) were obtained. 
All samples were collected in Red-Tip Heparinized Micro-Hematocrit 
capillary tubes (Fisher Scientific Co., Pittsburg, PA). The patency 
of the carotid catheter was maintained with heparinized saline (30 /ml). 
Approximately 0.20 ml of heparinized saline was given to each animal 
via the carotid catheter after each blood sampling to replace the vdliume 
of blood loss. Hematocrit was measured on every blood sample. Blood 
pressure was measured at T = 15, 45, 75, and 105 minutes. Blood 
pressure measurements were made with a U-tube mercury manometer connected 
by rigid tubing to the carotid artery catheter. The manometer was 
calibrated daily to correct for changes in barometric pressure. 
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In a separate study, the diuretic effectiveness of the doses 
used for Groups la and lb and Ila and 11b were evaluated (Figure 3). 
Experimental animals underwent neck surgery as outlined above, 
but nephrectomy was not performed. Instead, a lower midline 
abdominal incision was made and a catheter inserted into the bladder, 
taking care not to disturb the ureters. Following an equilibration of 
approximately 60 minutes, two carotid blood samples (P-j and P2) were 
obtained 30 minutes apart (T = 15 and 45 minutes) for analysis of 
baseline Na and K concentrations. Urine was collected over 30 minute 
intervals. Two baseline urine collections (U-j and U^) were obtained 
at T = 30 and 60 minutes (see Figure 3) and were analyzed for Na and 
K concentrations and volume. At T = 60 minutes, a chosen dose of 
diuretic or an equivalent volume of its respective control was 
given intravenously over approximately one minute. Four more carotid 
blood samples (PE-j , PE^, PE^, and PE^ at T = 75, 1 05, 135, and 165 
minutes) and four more urine collections (UE-j , UE^, UE^, and UE^ at 
T = 90, 120, 150, and 180 minutes) were taken for analysis as 
outlined above. An effective diuretic dose was a dose that resulted 
in both an increase in urine volume and an increased natriuresis. 
The dose of spironolactone used (10 mg/kg) was arbitrarily 
chosen as approximately five to ten times the average effective oral 
mg/kg dose in man. Administration of spironolactone to test animals 
was via a subcutaneous route. Each animal was given two doses of the 
diuretic, the first 24030 hours prior to study and the second 
approximately 210 minutes prior to KC1 infusion. 
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Bumetanide, like furosemide, is a 3-aminobenzoic acid derivative, 
but bumetanide has a higher milligram potency. It is equipotent with 
furosemide at l/40th the molar dose (119). However, bumetanide is 
ineffective as a diuretic in the rat (120). The dose of bumetanide 
used (0.25 mg/kg) was arbitrarily chosen as approximately 2.5 times 
the intravenous dose known to produce a diuresis in dogs (121). 
Analytic methods 
Hematocrits were measured by collecting blood samples in 
heparinized capillary tubes which were spun for three minutes on a 
Micro Hematocrit IEC MB Centrifuge (Demon/IEC Division, Needham Heights, 
MA), and subsequently read on a Micro Hematocrit Reader. 
Plasma and urine Na and K concentrations were measured with a 
flame photometer (Instrumental Laboratories, Watertown, MA) using an 
internal lithium standard. Blood pH and plasma bicarbonate levels 
were not obtained. 
Calculations 
In Groups la, lb, 11a, 11b, IVa, and IVb, mean baseline plasma 
Na and K concentrations were obtained by averaging two measurements 
obtained 15 minutes apart (B-j and B£) during the 30 minutes after 
animals had received their respective drugs or control substances, 
but before KC1 infusion. In Groups Ilia and 111b, mean baseline plasma 
Na and K concentrations were obtained in identical fashion in the 30 
minutes prior to KC1 infusion; in this case the drug and its control had 
been given at 24-30 hours prior to study and again at 210 minutes prior to 
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KC1 infusion. In all groups, plasma Na and K increments above 
the baseline mean at T = 75, 90, 105, and 120 minutes were calculated 
for each animal. The rise in plasma K concentration at the end of 
each timed interval was used as an index of K tolerance. Changes in 
plasma Na and K concentrations at these times as well as changes in 
hematocrit and blood pressure were calculated for all animals. Results 
of each group were then compared to its respective control group and 
analyzed by the Student t-test. Results are listed in Tables 1 and 2. 





Mean body weight in each group a 
from its respective control group b. 
study were: 
Group la 241.3+4.1 grams 
I la 234.3 + 7.6 grams 
Ilia 247.0+4.1 grams 
IVa 235.0 + 4.7 grams 
was not significantly different 
Mean weights at the time of 
lb 242.2 +4.3 grams 
IIb 233.7 + 6.7 grams 
Illb 246.8 + 3.7 grams 
IVb 236.3 + 5.2 grams 
Blood pressure 
Mean blood pressures during the equilibration period prior to 
administration of a diuretic, during the baseline period immediately 
following equilibration, and at the end of the study were compared 
to respective controls. Results are listed in Table 1. As can be 
seen, mean blood pressures in each group a did not differ 
significantly from its respective control group b. 
However, it should be noted that in group I la (HCTZ) and 11b 
(HCTZ control) there was a significant fall in blood pressure in both 
groups (-14.3 + 3.4 and -18.3 + 3.3 mm Hg, respectively) immediately 
following administration of either the drug or its control. This was 
in contrast to all other groups where no such change in blood pressure 
was observed, and was probably due to the vasodilatory effects of the 
fairly large ethanol percentage required to dissolve the HCTZ. However, 
blood pressures in group I la did not differ significantly from its 
control group 11b, and by the end of the study blood pressures in both 
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groups had risen to levels comparable to the other groups. 
Hematocrit 
The mean hematocrit in each group a at the beginning of the 
study was not significantly different from its respective control 
group b. Mean hematocrits at the end of the study and the increment 
between initial and final hematocrits were also not significantly 
different between experimental and control groups. 
KC1 dose 
The amount of KC1 infused was similar in all groups, and ranged 
between 0.17 + 0.1 mEq/100 gm body weight/hour. 
Potassium loading study 
Mean plasma K and Na concentrations were similar in all groups 
during the baseline period (see Table 2). The results of the potassium 
loading studies are shown in Table 2 and Figures 4-7. 
The maximal increment in plasma K concentration after one hour 
of KC1 infusion ( AT^) is listed for each group in Table 2, and was 
similar in each group. As can be seen graphically in Figures 4-7, 
the rise in plasma K concentration during KC1 infusion in the groups 
of rats given diuretics closely approximated the rise in plasma K 
in their respective controls. Differences in increments between 
plasma K at given time intervals and plasma K during baseline periods 
(AT.|- AT^) were not statistically significant. 
Plasma Na concentration at baseline varied from 137.2 +_ 2.7 to 
143.2 +1.30 mEq/L. There were no significant changes in plasma Na 




It has been a long standing assumption that diuretics have little 
effect on electrolyte transport outside the kidney (122). However, in 
view of the fact that more needs to be known regarding their mechanisms 
of action within the kidney and their effects of electrolyte homeostasis, 
further study of their actions both within the kidney and in extrarenal 
tissues is warranted. 
The purpose of this study was to examine the effects of diuretics 
of three different chemical families on extrarenal potassium disposal. 
The results indicate that furosemide, bumetanide, hydrochlorothiazide, 
and spironolactone at the doses employed do not significantly alter 
the ability of the acutely nephrectomized rat to tolerate a potassium 
load. The increments in plasma K following intravenous KC1 administration 
were not significantly different in animals given diuretics as compared 
to controls given no diuretics. 
While the present study shows no significant changes in potassium 
disposal with the diuretics used, there is information in the medical 
literature that made us suspect that these agents could have an 
extrarenal effect on potassium homeostasis. Hypokalemia is a common 
complication of diuretic therapy in man (120) and is generally 
attributed to potassium losses in the urine. However, there have been 
suggestions made in recent years that the etiology of the observed 
hyperkalemia may not be as simple as an increase in potassium excretion, 
and that changes in internal potassium balance may be among the 
extrarenal effects which diuretics could possess. Since the reasons 
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for pursuing an extrarenal effect on potassium disposal differ with 
each diuretic, the three families of diuretics used in this study will 
be discussed separately here. 
I. Furosemide and Bumetanide 
Furosemide, like the other "high ceiling" diuretics including 
bumetanide (Figure 1), inhibits sodium and chloride reabsorption in 
the thick ascending loop of Henle (122,123). Although the mechanism 
of its action is not fully understood, it appears to involve primarily 
inhibition of the active transport of Cl at the luminal membrane of 
tubular cells in the ascending limb (122,123), resulting in increased 
flow to the distal tubule and collecting system. This causes an 
impairment of urinary concentrating and diluting ability and increased 
urinary Na, Cl, K, and water losses. Like the rest of the high 
ceiling diuretics, the diuretic potency of furosemide far exceeds 
diuretics of other classes (124,125). Bumetanide appears to have an 
action similar to that of furosemide, and has a higher milligram 
potency in dogs and in man (119,120). 
A number of extrarenal effects of furosemide on systemic hemodynamics 
have been described, including its action on pre-load reduction (1) and 
its action as an antihypertensive agent (126-128). As mentioned 
earlier, furosemide has been shown to induce acutely an increase in 
venous capacitance which precedes its natriuretic effect (1,129,130). 
The observed decrease in left atrial and left ventricular filling 
pressures is probably due to increased renal blood flow as well as to 
increased peripheral venous capacitance (1,131). As noted by Dikshit 
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et a 1. (1), this furosemide-induced hemodynamic effect is more rapid 
than the inotropic effect of digitalis, and may be more beneficial 
in the setting of acute myocardial infarction not only due to its 
effects on relieving pulmonary edema and congestion but also to its 
relative lack of demand on myocardial oxygen requirements. 
Furosemide has been used widely as an antihypertensive agent. 
Immediate decreases in blood pressure are probably mediated by volume 
changes. However, the mechanism of its hypotensive effect in chronic 
use is felt to be distinct from its diuretic activity. This is 
supported by the observation that furosemide in large doses has been 
noted to be an effective antihypertensi ve in the presence of renal 
insufficiency (1 32,1 33). Although the effect of decreasing blood 
pressure is not fully understood, it probably involves a number of 
factors, including increased peripheral venous capacitance (1,134), 
decreased peripheral arteriolar resistance (126,135), and increased 
peripheral blood flow (126,1 35). 
There has recently been described an electrolyte cotransport 
system capable of producing net sodium, potassium, and chloride 
movement intracel lularly (10,14,15,19,108-113). The in vivo 
physiologic significance of this mechanism is not known. However, 
it has been postulated that it acts in opposition to the Na-K ATPase 
which extrudes Na from dells, and that it may have a significant 
role in the regulation of cellular volume as well as in electrolyte 
balance (11,12,112,113). Moreover, it is of interest that the mechanism 
has been demonstrated to exist in the loop of Henle (19) and is 
inhibited by furosemide. The cotransport is probably the mechanism 

34 
of "active" chloride transport in the ascending limb. This postulate 
does not necessarily contradict evidence that chloride transport in 
the thick ascending loop is dependent in some way on Na-K ATPase 
activity (123). As outlined by Aronson (118) and Crane (136), secondary 
active transport is by definition not directly dependent on active 
metabolic expenditure. However, there must be an indirect linkage 
to some such primary active process in order for it to continue. For 
example, many known secondary active transport systems involve coupling 
of the transport of substances against their electrochemical potential 
differences to the movement of sodium down its electrochemical gradient. 
In order to maintain the sodium gradient oriented to allow sodium flux 
into cells, an active transport mechanism to extrude sodium from cells 
must exist. Otherwise the gradient would dissipate and any transport 
process coupled to sodium movement would cease. For example. Crane 
has proposed this form of couple transport as the mechanism of active 
intestinal glucose absorption (136). In the intestinal epithelium, 
a primary active mechanism in the basolateral membrane actively pumps 
Na out of cells at the expense of ATP, hence maintaining the Na 
electrochemical gradient directed toward allowing Na movement into 
cells. In this manner, secondary active transport of such compounds 
as glucose can continue across the luminal membrane. Frizzell et al. 
(137) have proposed a similar mechanism for active chloride transport. 
A similar type of transport may be effective in the ascending loop 
of Henle. That is, the postulated Na-K-Cl cotransport mechanism 
may be linked secondarily to a primary active Na-K ATPase pump. 
Hence, inhibition of the pump, for example by ouabain, would indirectly 
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but surely block Cl uptake in the ascending limb as has been 
observed (123). 
As mentioned, the physiologic significance of this cotransport 
system is not known. However, if the mechanism is an important 
regulator of electrolyte balance not only in the loop of Henle as 
has been suggested, but in the whole animal as well, then one would 
expect that inhibition of the transport could have significant i n vi vo 
consequences. Of particular interest to this study are the possible 
effects of cotransport inhibition on extrarenal potassium homeostasis. 
The nephrectomized rat model used for the present study excludes 
renal effects on electrolyte balance. If blocking the cotransport 
mechanism with furosemide or bumetanide causes inhibition of potassium 
movement into cells, then one would expect to see a decrease in K 
tolerance in response to an acute K load. There is precedent to look 
for these effects in the whole animal in that the cotransport system 
is known to exist extrarenally in human red blood cells (14-18). 
However, as is evident in Figures 4 and 5, this was not the case with 
either furosemide or bumetanide. The timed increments in serum 
potassium observed in both furosemide-treated and bumetanide-treated 
animals were not significantly different from the increments observed 
in their controls. These results argue against the postulate that 
the cotransport mechanism is a major regulator of in vivo extrarenal 
K homeostasis. 
It is not surprising that bumetanide failed to cause any significant 
change in K tolerance. As pointed out by Palfrey et al. (10), the 
ability of the aminobenzoic acid derivatives to inhibit the cotransport 
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mechanism is directly related to diuretic potency. Bumetanide is 
not effective as a diuretic in the rat (120), and the results obtained 
here support their conclusion. However, furosemide is known to be an 
effective and potent diuretic in the rat, and it was expected that it 
might cause a change in K tolerance. 
It should be noted that the cotransport mechanism has never been 
studied in the whole animal. It is certainly possible that it does 
function as an important regulator of extrarenal electrolyte 
homeostasis, but that its effects on electrolyte balance are not 
detectable by the techniques used here. As outlined previously, the 
mechanism has been studied in isolated cell systems in which other 
factors known to influence K homeostasis in vivo can be controlled. 
The physiologic constraints of using a whole animal model can 
be numerous. 
Keeping this in mind, the fact that no effect on K tolerance was 
seen does not necessarily imply that the cotransport system is not 
operative. It may be that other regulators of K homeostasis are either 
more important in vivo or dominate K regulation in this particular 
setting. For example, the stress of anesthesia and surgery in these 
animals has been documented to result in persistently elevated 
epinephrine levels (30). -adrenergic agents are known to stimulate 
cotransport in isolated cell systems; their effects oppose those of 
such agents as furosemide. Therefore, in the experimental set-up used 
here, one would expect the cotransport mechanism to be maximally 
stimulated by epinephrine prior to administration of furosemide. The 
results obtained showing no change in K tolerance in furosemide-treated 
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animals when compared with controls may be explained by this maximal 
^-adrenergic stimulation. This may indicate either that ^5-adrenergic 
stimulation is the dominant regulator of the cotransport mechanism 
or that ^-adrenergic stimulation is not reversible at the doses of 
furosemide used. This raises another issue. The transport mechanism 
is known to be inhibited by concentrations of furosemide in the range 
-5 -3 
of 10 - 10 M (10). Furosemide, like other organic acids, is 
actively secreted into the proximal tubule (138) and concentrated in 
the tubular lumen, and is known to inhibit chloride reabsorption at 
-6 -5 
concentrations of 10 - 10 M in the lumen of the ascending limb (122). 
The volume of distribution of furosemide is 10% body weight, and in 
plasma, the drug is 95% protein bound (139). At the dose used in these 
experiments (20 mg/kg), one would estimate that the concentration of 
_5 
free circulating drug would be approximately 3 X 10 M. This is near 
the lower limit of concentrations at which an effect is seen on 
cotransport in isolated cell systems, and it is possible that the free 
fraction of drug in this experimental setting may not have been 
sufficient to effect cotransport inhibition. It would be of interest 
to accurately determine if concentrations obtained with the dose used 
are within the range known to produce inhibition in vitro; however, 
this was beyond the scope of the present experiments. 
The role of cotransport on electrolyte homeostasis merits further 
work. It would be interesting to repeat these experiments in a setting 
in which factors which might interact or interfere with its effects 
could be better controlled. In particular, its significance in tissues 
known to participate in K storage and regulation, such as muscle or liver. 
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should be pursued. There are also a number of ways in which the 
design of these experiments could be modified and possibly improved. 
For example, pH, bicarbonate levels, and hormone levels were not 
measured in the present study. Had there been significant changes 
in K tolerance noted, these would have been explored more thoroughly. 
Also, it is possible that following another electrolyte besides K 
would be informative. The postulated stoichiometry of the system is 
IK : INa : 2C1. It may be that the changes brought about in K 
balance were too small to be quantitated in the face of the large 
K load administered. Under these circumstances, measuring chloride 
concentrations might have yielded more significant results, since 
twice as much Cl is transported as K. If K infusion could be used 
in the same manner to stress the cotransport system, but with an 
anion other than Cl, then monitoring response to the inhibition of 
the cotransport mechanism by following chloride concentration might 
be more fruitful. 
II. Hydrochlorothiazide 
Thiazides are among the most commonly used diuretic agents. The 
mechanism of the action of thiazides within the kidney is not fully 
understood, but appears to involve inhibition of reabsorption of 
sodium and chloride in the distal tubule via an interaction with 
specific renal receptors (120,140). 
Numerous extrarenal effects of thiazides have been described. 
Their use in the treatment of hypertension is perhaps the most obvious. 
Initially thiazides cause a decrease in blood volume and a drop in 
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cardiac output due to their diuretic activity. However, during chronic 
therapy, cardiac output returns to normal and peripheral resistance 
falls (141,142), thereby maintaining a relatively hypotensive state 
(3,4). This effect is not related temporally or in magnitude to the 
diuretic effect per se, and persists after normalization of the 
cardiac output. 
Other extrarenal effects of thiazides include an association of 
their use with impaired glucose tolerance (144-147). The mechanism of 
this effect is not known but is felt perhaps to involve production of 
hypokalemia which then limits insulin secretion (147,148). Thiazides 
also have major effects on metabolic balance. Koppel et al. (149) 
have demonstrated an extrarenal effect of thiazides on calcium balance. 
In patients with end stage renal disease and hypertension treated with 
thiazides, a distinct hypercalcemic effect was noted. These authors 
postulate that this may have resulted from potentiation of the action 
of parathyroid hormone in these patients who often have underlying 
parathyroid gland hyperplasia secondary to their renal disease. A 
hypermagnesemic effect was also noted in these patients, which was 
felt to be attributable to decreased renal Mg excretion and perhaps to 
an increased release of Mg from bone or soft tissues. 
Of most interest to the present study is the suggestion by 
several investigators that thiazides have an extrarenal effect on 
potassium homeostasis. There is significant controversy over what 
effect thiazides have on serum and total body potassium. Some 
investigators report significant reductions in total body potassium 
with thiazide use (150-152) while others report no reduction in total 
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body K (151,153-155). Oh and Carroll (156) have pointed out that a 
mathematically significant fall in total body K may not be physiologically 
significant. Nevertheless, the hazard of hypokalemia in patients 
on thiazides is evident, particularly in the setting of myocardial 
disease, hypertension, digitalis use, and liver cirrhosis in which they 
are often used. 
It is a common clinical observation that a significant number of 
patients using thiazide diuretics have a fall in serum potassium (157). 
Chronic hypokalemia is thought to result from increased aldosterone 
secretion due to elevated renin levels secondary to chronic diuretic- 
induced oligemia (158). This is supported by the work of Sweet and 
Gaul (157) who noted that thiazide-induced hypokalemia could be corrected 
by adding a ^,-adrenergic blocking agent, theoretically by decreasing 
plasma renin activity. However, these authors point out that the 
diuretic produced a lowering of serum potassium even when plasma renin 
was suppressed to pre-treatment levels by ^-blockade. It is striking 
that thiazide-induced hypokalemia is so commonly observed in view of 
multiple demonstrations that total body potassium is unchanged even 
with prolonged thiazide use. Recently a number of groups have 
postulated that the hypokalemia associated with thiazide administration 
may reflect redistribution of potassium rather than an absolute reduction 
of total body potassium (23,24,159). 
In a study on the use of thiazides in hypertensive patients, 
Talso and Carballo (159) noted that 85% of these patients demonstrated 
a decrease in serum potassium concentration, yet simultaneous 
determinations of total body potassium revealed no significant changes 
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in the body content of the cation. They postulated that alterations 
in acid-base balance, notably the metabolic alkalosis often observed 
with thiazide use, might have a significant effect on the production 
of hypokalemia by causing redistribution of potassium. However, 
while alterations in extracellular pH and replacement of hydrogen ion 
in the form of ammonium chloride did favorably alter serum potassium 
status during thiazide administration, these authors noted that 
supplementation of the extracellular hydrogen ion concentration was 
not the sole mediator of the extracellular potassium concentration, 
and suggested that other factors, including perhaps an effect of 
thiazides on the permeability of the cell membrane to potassium, were 
involved in determining the level of serum potassium. 
There have been a number of cases described in the pediatric 
population of hyperkalemia occurring in the setting of normal renal 
and adrenal function and associated with acidosis and hypertension (21, 
22). Recently, the phenomenon of hyperkalemia following renal 
transplantation but unrelated to graft rejection has been noted in a 
significant percentage of post-transplant patients (23). DeFronzo et 
al. (23) noted that this was present in 23 of 75 consecutive transplant 
patients within three months of transplantation, and was present in 
the absence of acidosis, renal insufficiency, and rejection. It was 
also noted that the observed hyperkalemia was corrected by administration 
of hydrochlorothiazide. The authors have postulated that the transient 
defect in tubular K secretion observed post-transplantation was due 
either to decreased tubular basolateral membrane K uptake or to decreased 
luminal membrane permeability to K, and that the effectiveness of 
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thiazide in reversing the hyperkalemia may be due to alteration of 
either or both of these cellular defects. The authors also point out 
the possibility that thiazides may have actions on extrarenal potassium 
distribution which could account for or at least contribute to the 
observed decrease in serum K. 
In another recent study, Farfel et al. (24) have described two 
cases in which hypertension and hyperkalemia associated with normal 
renal function, low plasma renin activity, and normal plasma 
aldosterone levels were corrected with thiazide administration. The 
authors have postulated that the etiology of the observed syndrome 
lies in a defect in cell membrane potassium transport. Of particular 
interest to the present study was the fact that thiazide administration 
caused serum K to fall to normal values in the absence of a significant 
increase in urinary K excretion in either patient. In general it has 
been assumed that the hypokalemic effect of diuretics is due to their 
action of increasing renal K losses. However, these results support 
the theory that an extrarenal effect of thiazides causing cellular K 
redistribution plays a significant role in their hypokalemic effect. 
There is, then, precedent to believe that thiazides may have 
extrarenal effects on potassium homeostasis. The model used for the 
present study was chosen for its exclusion of renal effects. If the 
hypokalemic effect of thiazides is caused by cellular redistribution of 
potassium, one would expect that tolerance to a potassium load would 
be improved in their presence. However, as is evident graphically in 
Figure 6, this was not the case. The timed increments in serum 
potassium observed in thiazide-treated animals were not different from 
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the increments observed in their controls. These data argue against 
the postulated extrarenal hypokalemic effect of thiazides. It is 
unlikely that the dose of hydrochlorothiazide was insufficient 
since this is a maximally natriuretic dose (143), and since it is 
several times greater than the usual daily oral dose in human 
subjects. However, it is possible that an effect does exist, but 
that its magnitude is not great enough to maintain a significant 
lowering of plasma potassium in the face of the large KC1 infusion 
used in these experiments. 
III. Spironolactone 
The introduction of the aldosterone-antagonist spironolactone in 
1957 (160) represented one of the first cases in which knowledge of the 
biochemical structure of a compound with known biologic effect was 
used to search deliberately for and synthesize a specific pharmacologic 
agent. In view of the fact that aldosterone itself had not been 
isolated until 1952 (161 ), this was a remarkable accomplishment. 
Spironolactone is a competitive inhibitor of aldosterone. It 
does not inhibit secretion of aldosterone or of any of the other adrenal 
steroids, but antagonizes the effect of aldosterone by combining with 
specific target tissue receptor sites (162,163). In the kidney it 
antagonizes the aldosterone-stimulated K secretion and Na reabsorption 
that occurs in the distal tubule (120). In the absence of aldosterone, 
spironolactone has no effect on renal electrolyte excretion (163), but 
if aldosterone is present spironolactone promotes a natriuresis 
regardless of the level of mineralocorticoid (164). Potassium retention 
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occurs only if there is a concomitant low sodium intake, and this 
action can be overcome by sufficiently increased levels of aldosterone 
(165,166). Use of spironolactone may induce hyperkalemia; however, 
with chronic use serum K levels return toward pre-treatment levels 
(1 67,168). 
Spironolactone induces a modest hypotensive effect in most 
hypertensive patients, and has a synergistic hypotensive effect with 
other diuretics (169). That this action is distinct from a purely 
volume depleting effect due to its diuretic action is shown in that 
expansion of the extracellular fluid volume with dextran, plasma, or 
saline does not abolish its effect (170). 
Evidence exists that mineralocorticoids increase extrarenal 
tissue K uptake in the whole animal (25,27-29). As this has been 
discussed in the introduction, studies supporting this hypothesis will 
not be reiterated here. The availability of spironolactone as a 
selective inhibitor of aldosterone activity can be used as a tool to 
further investigate this theory. Moreover, in view of the fact that 
there is precedent in the example of insulin to believe that basal 
levels of hormones may play a role in K regulation, it is of interest 
to examine the effects of selective aldosterone blockade on extrarenal 
potassium disposal. 
If, as recently postulated, extrarenal potassium tolerance is 
impaired in the setting of aldosterone deficiency (25,30), then one 
would expect to see a decrease in the ability of animals given 
spironolactone to tolerate a potassium load. The results of the 
present study indicate, however, that administration of spironolactone 
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did not significantly alter the hyperkalemic response in nephrectomized 
rats given an acute potassium load. As can be seen in Figure 7, the 
timed increments in plasma potassium observed in spironolactone- 
treated animals were not different from the increments observed in 
control animals. The conclusion to be drawn from these results is 
that blockade of peripheral aldosterone activity does not impair the 
ability of extrarenal tissues to dispose of potassium as has been 
suggested. This argues against the hypothesis that aldosterone plays 
an important role in extrarenal potassium regulation. 
The possiblity exists, of course, that the results obtained here 
do not accurately reflect the effects of aldosterone inhibition. It 
has been noted clinically as well as experimentally that several days 
of spironolactone administration are required to observe the effects 
of aldosterone inhibition (169,171). Although the doses used in 
the present study should have been sufficient to induce aldosterone 
inhibition, it is possible that a longer duration of administration 
is necessary. This was avoided in this study to prevent the effects 
of spironolactone-induced increases in body potassium stores which 
are observed with long term use of the drug. 
Another possible explanation for failure to see decreased K 
tolerance is the method used to administer the drug. French and 
Manery (172) have pointed out that intermittent administration of 
depot preparations of aldosterone are not reliable in producing its 
mineralocorticoid effect. It would not be unreasonable to consider 
that this might also be true of spironolactone, since the compounds 
are chemically very similar. One means of checking this would be to 
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The effects of furosemide, bumetanide, hydrochlorothiazide, 
and spironolactone on extrarenal potassium homeostasis were studied 
in acutely nephrectomized rats. None of these agents altered the 
ability of experimental animals to tolerate a potassium load. We 
conclude that, within the limits of the experimental design of this 
study, diuretics do not modify extrarenal potassium disposal. This 
study provides no evidence that the changes in serum potassium 
concentration observed with diuretic use are caused by any changes 




Blood Pressure (mm Hg) 
Equilibrium Baseline T^ 
Group mean (E)_mean (B)_ 
Increment in Blood Pressure 
(mm Hg) 
(E) - (B) T1 - (E) 
Ia 100.0 + 5.3 1 04.0 + 3.9 107.0 + 3/1 
lb 102.3 + 5.6 103.0 + 5.8 106.7 + 7.0 
4.0 + 4.2 3.0 + 3.0 
0.7 + 2.6 3.7 + 4.2 
I Ia 106.0 + 7.2 87.0 + 8.8 94.7 + 5.7 -14.3 + 3.4 
11 b 110.3 + 10.9 94.3 + 11.7 103.3 + 8.4 -18.3 + 3.3 
6.0 + 6.2 
9.0 + 3.8 
Ilia 111.7 + 7.6 113.7 + 6.1 115.0 + 5.6 
Illb 111.3 + 5.8 111.3 + 4.1 115.0 + 2.5 
3.0 + 5.8 1.3 + 3.0 
-0.3 + 2.2 2.0 + 3.5 
IVa 112.0 + 6.1 111.3 + 9.4 108.7 + 10.7 -0.6 + 6.4 -2.7 + 2.7 
IVb 110.7 + 11.6 100.7 + 11.0 103.3 + 8.8 -6.7 + 2.4 2.7 + 8.2 
Table 1. Blood pressure during equilibrium period (E), during 
baseline period (B), and at the end of study (T»), 
and increments in blood pressure between periods 
(E) and (B) and between periods T, and (E). 




Basel ine mean 
plasma K 
Increment in plasma K above baseline 
(mEq/L) 
Group (mEq/L) &T-j 
la 5.21 + .13 .71 + .14 
lb 4.95 + .11 .96 + .18 
I la 4.57 + .15 .78 + .12 
11 b 4.91 + .14 .67 + .17 
Ilia 5.12 + .11 .88 + .07 
111 b 4.83 + .19 .97 + .13 
IVa 4.87 + .51 .61 + .16 
IVb 4.66 + .44 1.02 + .03 
AT2 aT3 
^T^ 
1.89 + .19 2.60 + .16 3.11 + .17 
1 .89 + .05 2.58 + .10 3.21 + .14 
1.50 + .12 2.20 + .13 2.74 + .18 
1.50 + .17 2.10 + .17 2.69 + .26 
2.15 + .06 2.85 + .07 3.32 + .12 
1.92 + .20 2.68 + .21 3.08 + 122 
1.59 + .18 2.55 + .16 3.31 + .25 
1.81 + .08 2.94 + .15 3.67 + .20 
Table 2. Baseline mean plasma K concentrations. 
Increments in plasma K concentrations above baseline at 
timed intervals during KC1 infusion. 










Chemical structures of furosemide, hydrochlorothiazide, 


















































































































































Minutes of KCI Infusion 
Figure 4 
Figure 4. Increment in plasma K concentration above baseline in 
control (#-• ) and furosemide-treated (o—o) animals. 





















Minutes of KCI Infusion 
Figure 5 
Figure 5. Increment in plasma K concentration above baseline in 
control (•—• ) and bumetanide-treated (o—o) 




















Minutes of KCI Infusion 
Figure 6 
Figure 6. Increment in plasma K concentration above baseline in 
control ( «—• ) and hydrochlorothiazide-treated ( o—o ) 
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